Studies have also shown that a higher ratio of CD4+/CD8+ T-cells to PD-L1 tumor expression is an independent predictor of better 4-year OS of DLBCL patients treated with Standard of Care (SOC) chemotherapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) (23, 24). Here, CD8A is linked to neoplasm.